Redmile Group | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Redmile Group/Activity

Redmile Group Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

6 investments· JUN 2025 – AUG 2026Show all

Investment

Participated in Abcuro's $66M Series D financing led by New Leaf Venture Partners to advance ulviprubart for inclusion body myositis.

Abcuro

Abcuro Redmile Group

finsmes.comAUG 18, 2026

AUG 18, 2026

Investment

Participated as a new investor in Obsidian Therapeutics' $350M private placement concurrent with its merger with Galera Therapeutics.

Obsidian Therapeutics

Obsidian Therapeutics Redmile Group

businesswire.comAUG 3, 2026

AUG 3, 2026

Investment

Participated in Absci's $100M underwritten public offering alongside Eli Lilly, Adage, BVF Partners, and others.

Absci

Absci Redmile Group

globenewswire.comJUN 24, 2026

JUN 24, 2026

Investment

Co-led Ambrosia Biosciences' $100M oversubscribed Series B financing for its oral small-molecule GLP-1 program.

Ambrosia Biosciences

Ambrosia Biosciences Redmile Group

finsmes.comMAR 31, 2026

MAR 31, 2026

Investment

Continued as an existing backer in Electra Therapeutics' $183M Series C, co-led by Nextech and EQT Life Sciences.

Electra Therapeutics

Electra Therapeutics Redmile Group

globenewswire.comOCT 22, 2025

OCT 22, 2025

Investment

Participated as an existing investor in Neuron23's $96.5M Series D financing for its Parkinson's disease pipeline.

Neuron23

Neuron23 Redmile Group

finsmes.comJUN 24, 2025

JUN 24, 2025